Thermo Fisher Scientific Human LGI4 Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to 17 amino acids near the carboxy terminus of human LGI4.
PEP-0634 can be used as a blocking peptide with polyclonal antibody PA5-20514.

Target Information

The leucine-rich, glioma inactivated gene 4 (LGI4) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four highly related proteins containing leucine-rich repeats (LRRs), which are similar to other transmembrane signaling molecules and receptors.
LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autosomal dominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms.
Despite its high homology with LGI1 and similar expression pattern, mutations in LGI4 have not been found to be associated with ADTLE. However, the LGI4 gene is located in a region linked to benign familial infantile convulsions.
A GC-to-AT polymorphism has been correlated with childhood absence epilepsy. Decreasing LGI4 expression in cultured cells inhibits myelination, indicating that LGI4 may play a role in neural development.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.